Literature DB >> 2878363

p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity.

D F Stern, P A Heffernan, R A Weinberg.   

Abstract

The neu oncogene was originally identified in cell lines derived from rat neuroectodermal tumors. neu is related to but distinct from the c-erbB gene, which encodes the epidermal growth factor (EGF) receptor. neu encodes a protein, designated p185, that is serologically related to the EGF receptor. Identification of the normal homolog of p185 encoded by the neu proto-oncogene enabled us to compare the product of the neu proto-oncogene with the mutated version specified by the neu oncogene and with the EGF receptor. The normal form of p185 was structurally similar to its transforming counterpart, indicating that activation of the neu oncogene did not cause major structural alterations in the gene product. Both normal and transforming forms of p185 were associated with tyrosine kinase activity, supporting the idea that normal p185 functions as a growth factor receptor. p185 differed both structurally and functionally from the EGF receptor. p185 and the EGF receptor had distinct electrophoretic mobilities when synthesized under normal culture conditions or in the presence of tunicamycin. EGF did not stimulate increased turnover of p185 and did not bind quantitatively to p185. A number of other growth factors failed to stimulate degradation of p185 or tyrosine phosphorylation of p185 and are therefore unlikely to be ligands for p185.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2878363      PMCID: PMC367701          DOI: 10.1128/mcb.6.5.1729-1740.1986

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  63 in total

1.  Comparison of the expression of the src gene of Rous sarcoma virus in vitro and in vivo.

Authors:  B M Sefton; K Beemon; T Hunter
Journal:  J Virol       Date:  1978-12       Impact factor: 5.103

2.  Molecular mechanism of mitogen action: processing of receptor induced by epidermal growth factor.

Authors:  M Das; C F Fox
Journal:  Proc Natl Acad Sci U S A       Date:  1978-06       Impact factor: 11.205

3.  Transforming gene product of Rous sarcoma virus phosphorylates tyrosine.

Authors:  T Hunter; B M Sefton
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

4.  Clonal cell lines from the rat central nervous system.

Authors:  D Schubert; S Heinemann; W Carlisle; H Tarikas; B Kimes; J Patrick; J H Steinbach; W Culp; B L Brandt
Journal:  Nature       Date:  1974-05-17       Impact factor: 49.962

5.  Antibodies to purified insulin receptor have insulin-like activity.

Authors:  S Jacobs; K J Chang; P Cuatrecasas
Journal:  Science       Date:  1978-06-16       Impact factor: 47.728

6.  Purification of human platelet-derived growth factor.

Authors:  H N Antoniades; C D Scher; C D Stiles
Journal:  Proc Natl Acad Sci U S A       Date:  1979-04       Impact factor: 11.205

7.  Affinity labeling of multiplication stimulating activity receptors in membranes from rat and human tissues.

Authors:  J Massague; B J Guillette; M P Czech
Journal:  J Biol Chem       Date:  1981-03-10       Impact factor: 5.157

8.  The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen.

Authors:  A L Schechter; D F Stern; L Vaidyanathan; S J Decker; J A Drebin; M I Greene; R A Weinberg
Journal:  Nature       Date:  1984 Dec 6-12       Impact factor: 49.962

9.  Epidermal growth factor-receptor-protein kinase interactions. Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity.

Authors:  S Cohen; G Carpenter; L King
Journal:  J Biol Chem       Date:  1980-05-25       Impact factor: 5.157

10.  Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts.

Authors:  C Shih; L C Padhy; M Murray; R A Weinberg
Journal:  Nature       Date:  1981-03-19       Impact factor: 49.962

View more
  85 in total

1.  Negative autoregulation of the neu gene is mediated by a novel enhancer.

Authors:  X Y Zhao; M C Hung
Journal:  Mol Cell Biol       Date:  1992-06       Impact factor: 4.272

2.  Down-regulation of cellular platelet-derived growth factor receptors induced by an activated neu receptor tyrosine kinase.

Authors:  L Lehtola; M Nistér; E Hölttä; B Westermark; K Alitalo
Journal:  Cell Regul       Date:  1991-08

3.  [Molecular protocol for HER2/neu analysis in breast carcinoma].

Authors:  Montse Verdú Artufel; Anna Colomer Valero; Ruth Román Lladó; Nadina Erill Sagalés; Miquel Calvo Llorca; Abelardo Moreno Carazo; Carlos Cordón Cardó; Xavier Puig Torrus
Journal:  Clin Transl Oncol       Date:  2005-12       Impact factor: 3.405

4.  EGFs and ERBBs--brief history and prospects.

Authors:  David F Stern
Journal:  Semin Cell Dev Biol       Date:  2010-10-21       Impact factor: 7.727

5.  Correlation of the structure of the transmembrane domain of the neu oncogene-encoded p185 protein with its function.

Authors:  P W Brandt-Rauf; S Rackovsky; M R Pincus
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

6.  neu protooncogene fused to an immunoglobulin heavy chain gene requires immunoglobulin light chain for cell surface expression and oncogenic transformation.

Authors:  J G Flanagan; P Leder
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

7.  Activation of Neu (ErbB-2) mediated by disulfide bond-induced dimerization reveals a receptor tyrosine kinase dimer interface.

Authors:  C L Burke; D F Stern
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

8.  Analysis of c-erbB2 protein content of human glioma cells and tumor tissue.

Authors:  H H Engelhard; M Wolters; P S Criswell
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

Review 9.  ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer.

Authors:  David F Stern
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-05-03       Impact factor: 2.673

10.  Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies.

Authors:  G D Lewis; I Figari; B Fendly; W L Wong; P Carter; C Gorman; H M Shepard
Journal:  Cancer Immunol Immunother       Date:  1993-09       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.